SAN DIEGO, CA / ACCESSWIRE / October 28, 2014 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB: INNV) announced today the acquisition of Vesele(R) from Trōphikōs, Inc., a company located in Florida. Vesele(R) is a proprietary, novel and safer oral dietary supplement to maximize nitric oxide's beneficial effects on sexual function and brain health. Vesele(R) contains a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine(R).
The beneficial effects of Vesele(R) on sexual and cognitive functions were confirmed in a four month US clinical survey study involving 152 patients (69 men and 83 women). Results from the clinical survey have indicated (1) improvement of erectile hardness and maintenance in men and increased sexual intercourse frequency with their partners and (2) lubrication in women, when taken separately by each. Positive effects on brain health were translated by an increase in recall of words and names.
"Vesele(R) is an oral dietary supplement which will be an ideal addition to our sexual health and vitality pipeline, as we continue to expand our portfolio of marketed products both in the US and through our existing partners internationally," said Dr. Bassam Damaj, President and Chief Executive Officer.
Vesele(R) will be offered initially through our online platform at www.myvesele.com and www.innovuspharma.com while the Company starts integrating the product into its retail and international platform said Mr. Robert Verfurth, Vice President of Sales and Marketing for the Company.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction and vitality products. The Company generates revenues from its lead products Zestra(R) for female arousal, and EjectDelay(TM) for premature ejaculation, and has a total of four marketed products in this space including Sensum+(TM) (for sales outside the U.S. only, Zestra(R) Glide and Vesele(R).
For more information, go to www.innovuspharma.com.
INNOVUS PHARMA'S FORWARD-LOOKING Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products, to successfully commercialize such products as Vesele(R), and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
###
Innovus Pharma Contact:
Kevin Holmes
Chesapeake Group
[email protected]
T: 410-825-3930
SOURCE: Innovus Pharmaceuticals, Inc.